Target intelligence / Profile preview

AMPA-type glutamate receptor (GluA2-lacking)

Molecular classification
Ion channel, Receptor, Ligand-gated ion channel, Glutamate receptor
01

Overview

AMPA-type glutamate receptors are tetrameric ligand-gated ion channels predominantly mediating fast excitatory neurotransmission in the central nervous system. Each receptor is formed by different combinations of the GluA1–GluA4 (GluR1–GluR4) subunits. The presence or absence of the GluA2 subunit dictates functional properties, most critically the receptor’s permeability to calcium ions (Ca2+). GluA2-lacking AMPA receptors—composed of GluA1, GluA3, and/or GluA4 subunits—are permeable to Ca2+, exhibit inward rectification, and play crucial roles in synaptic plasticity, but are also associated with increased neuronal vulnerability to excitotoxicity. GluA2-lacking AMPA receptors are key functional subtypes implicated in neurological diseases and represent important therapeutic targets[1][3][5].

Other names
GluA2-lacking AMPA receptorGluR2-lacking AMPA receptorCalcium-permeable AMPA receptor (CP-AMPAR)GluA2(–) AMPA receptorGluR2(–) AMPA receptor
02

Mechanism of action

Competitive antagonism at the glutamate binding site - Non-competitive (allosteric) antagonism at sites distinct from the agonist - Block of calcium-permeable ion flux through AMPAR channel

03

Biological functions

Fast excitatory synaptic transmissionSynaptic plasticityCalcium signalingNeuronal communication
04

Disease associations

Neurodegenerative diseaseNeurodevelopmental disorders (e.g., intellectual disability, autism spectrum disorder, epilepsy when GluA2 function is lost)ExcitotoxicityStroke/ischemiaEpilepsy
05

Safety considerations

Excessive inhibition may impair normal synaptic transmission and cognitionCa2+-permeable AMPARs are linked to increased excitotoxicity and neuronal death in certain pathological states (stroke, ALS, etc.)
06

Interacting drugs

Perampanel (approved AMPA receptor antagonist)

5 more in the full profile.

07

Biomarkers

Expression levels of GluA2 (GRIA2) mRNA/proteinPresence of Ca2+-permeable AMPA receptor currents (measured electrophysiologically)Loss of rectification (inward rectifying currents signifying GluA2-lack)

Beyond the preview

Go deeper on AMPA-type glutamate receptor (GluA2-lacking).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMPA-type glutamate receptor (GluA2-lacking).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call